Merck KGaA (Merck) and Opentrons Labworks have announced a partnership to automate assay kits on a ‘custom’ Opentrons Flex ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.

Buying a low-cost index fund will get you the average market return. But if you invest in individual stocks, some ...

Department of Health and Human Services (HHS) secretary nominee Robert F. Kennedy Jr. plans to continue to receive referral fees from a law firm that is suing pharma powerhouse Merck & Co. | ...

A recent health news roundup explores legal, financial, and strategic developments. Highlights include Robert F. Kennedy ...

The CEO of Germany's Merck KGaA on Thursday said a recovery in sales growth at its existing business means it can take a cautious approach to buying other companies, which are expensively priced. "We ...

Merck (MRK) and Eisai (ESAIY) announced results from the Phase 3 LEAP-015 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, ...

Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen ...

Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...

Ionic Liquids market Gains Momentum with Advancements in renewable Energy, Electronics, and Green Separation Technologies.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...